124 Views | 45 Downloads
Matthew C. Freeman, mattew.freeman@emory.edu
We thank the Institut de Recherche en Santé de Surveillance Epidemiologique et de Formation (IRESSEF) in Dakar, Senegal for their partnership in this study. We gratefully acknowledge the participants who gave their time and insights to help us better understand Senegal’s vaccine delivery system, along with facilitators from the Ministry of Health and Social Action for supporting this research, especially Dr. Ousseynou Badiane and Dr. Abdoulaye Mangane. In addition, we thank Sarah Chesemore, Anna Rapp, Tove Ryan, and Ethan Wong from the Bill and Melinda Gates Foundation; Kate Buellesbach, Nancy Fullman, Nathaniel Gerthe, Gloria Ikilezi, Caitlyn Mason, David Phillips, and Oliver Rothschild, Jordan-Tate Thomas, and Angela Wang from Gates Ventures; and the Vaccine Exemplars Research Advisory Group for their insights, specifically Agnes Binagwaho, Laura Craw, Carolina Danovaro, Anuradha Gupta, Heidi Larson, Penelope Masumbu, Kate O’Brien, Helen Rees, Lora Shimp, and Aaron Wallace.
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This work was supported by the Bill & Melinda Gates Foundation, Seattle, WA (OPP1195041) with a planning grant from Gates Ventures, LLC, Kirkland, WA.